ArticleClinicoEconomics and outcomes research : CEOR2019

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum].

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.